Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22 Prostate Adenocarcinoma 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 Leiomyoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 14 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 8 Irinotecan 8 Trastuzumab 7 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Erlotinib Hydrochloride 5 Sunitinib 4 Ramucirumab 4 Metformin 4 Gefitinib 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Panitumumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × relugolix × Clear all

NCT07302451 2026-01-06

REDI-CaP

National Cancer Institute, Naples

Phase 2 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡